<div id="readability-page-1">A recent study found that a combination of evorpacept alongside rituximab and lenalidomide (known as R 2) resulted in complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL). This is a significant improvement compared to the historical CR rate of approximately 50% for R 2 used alone. This indicates a promising outcome for patients with iNHL when the drugs are used in combination.</div>

ALXO

<p>A recent study found that a combination of evorpacept alongside rituximab and lenalidomide (known as R 2) resulted in complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL). This is a significant improvement compared to the historical CR rate of approximately 50% for R 2 used alone. This indicates a promising outcome for patients with iNHL when the drugs are used in combination.</p>

ALX Oncology reports promising results from Phase 2 Trial showing 92% complete response rate in indolent B-cell NHL patients.